Swiss National Bank
ATXS

Swiss National Bank’s Astria Therapeutics ATXS Stock Holding History

Swiss National Bank’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49,200
Closed -$263K – 2339
2025
Q1 		$263K Sell
49,200
-17,400
-26% -$122K ﹤0.01% 2391
2024
Q4 		$595K Buy
66,600
+7,700
+13% +$81.8K ﹤0.01% 2370
2024
Q3 		$648K Buy
+58,900
New +$655K ﹤0.01% 2368

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Swiss National Bank's ATXS Position: Q2 2025 in Review

Swiss National Bank sold out of Astria Therapeutics (ATXS) in Q2 2025, closing a stake of 49,200 shares — an estimated $263K sold.

Swiss National Bank first reported a position in ATXS in Q3 2024 and held it in 3 quarters. The position peaked at $648K in Q3 2024. 105 funds tracked by Wall St. Rank hold ATXS as of Q2 2025.

  • Swiss National Bank reported no remaining Astria Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Swiss National Bank sold 49,200 Astria Therapeutics shares in Q2 2025, an estimated $263K.
  • Swiss National Bank first reported a position in Astria Therapeutics in Q3 2024 and held it in 3 quarters.
  • Swiss National Bank's Astria Therapeutics position peaked at $648K in Q3 2024.
  • 105 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2025.

Based on Swiss National Bank's 13F filing for Q2 2025, filed 12 Aug 2025.